Abbott Laboratories (ABT) Revenue by Segment

Abbott Laboratories revenue by segment at a glance

In Q2 fiscal 2026 (the quarter ended June 30, 2026), Abbott Laboratories's largest business segment was Medical Devices, with $5.85 billion or 46% of revenue, up 9.0% from a year earlier. Next: Diagnostic Products (25%), Nutritional Products (17%) and Established Pharmaceutical Products (12%).

By region, Non-US brought in 59% and United States brought in 41% of revenue in Q2 fiscal 2026.

By country, Non-US brought in 59% and UNITED STATES brought in 41% of revenue in Q2 fiscal 2026.

The fastest-growing business segment from a year earlier was Diagnostic Products (+42.3%).

From company filings, in USD; latest quarter ended June 30, 2026; quarterly data from Q3 fiscal 2017.

Abbott Laboratories

ABTHealthcare

United States

Healthcare

Revenue breakdown

Fiscal quarters, from company filings

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Medical DevicesDiagnostic ProductsNutritional ProductsEstablished Pharmaceutical ProductsCardiovascular and Neuromodulation ProductsOther OperatingAll other segmentsCorporate and other

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Medical Devices	USD 5.85B	46.5%	+9.0%
Diagnostic Products	USD 3.09B	24.6%	+42.3%
Nutritional Products	USD 2.14B	17.0%	-3.1%
Established Pharmaceutical Products	USD 1.50B	11.9%	+8.4%
Corporate and otheri	USD 5.00M		+0.0%

Sum of items USD 12.59B; corporate items and eliminations USD 5.00M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Medical Devices	5.9B	5.5B	5.7B	5.4B	5.4B	4.9B	5.1B	4.7B	4.7B	4.5B	4.4B	4.2B	4.3B	3.9B	3.8B	3.6B	3.8B	3.6B	3.7B	3.6B	3.7B	3.3B	3.3B	3.2B	2.4B	2.9B	3.2B	3.1B	3.1B	2.9B	–	–	–	–	–	–
Diagnostic Products	3.1B	2.2B	2.5B	2.3B	2.2B	2.1B	2.5B	2.4B	2.2B	2.2B	2.5B	2.4B	2.3B	2.7B	3.3B	3.6B	4.3B	5.3B	4.5B	3.9B	3.2B	4.0B	4.3B	2.6B	2.0B	1.8B	2.1B	1.9B	1.9B	1.8B	2.0B	1.8B	1.9B	1.8B	–	1.3B
Nutritional Products	2.1B	2.0B	1.9B	2.2B	2.2B	2.1B	2.1B	2.1B	2.1B	2.1B	2.0B	2.1B	2.1B	2.0B	1.8B	1.8B	2.0B	1.9B	2.0B	2.1B	2.1B	2.0B	1.9B	1.9B	1.9B	1.9B	1.9B	1.9B	1.9B	1.8B	1.8B	1.8B	1.9B	1.8B	–	1.8B
Established Pharmaceutical Products	1.5B	1.4B	1.4B	1.5B	1.4B	1.3B	1.3B	1.4B	1.3B	1.2B	1.2B	1.4B	1.3B	1.2B	1.2B	1.3B	1.2B	1.1B	1.2B	1.3B	1.2B	1.1B	1.1B	1.1B	1.0B	1.0B	1.2B	1.2B	1.1B	992.0M	1.1B	1.2B	1.1B	1.0B	–	1.2B
Cardiovascular and Neuromodulation Products	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.4B	2.3B	2.4B	2.3B	–	2.2B
Other Operating	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	532.0M	486.0M	430.0M	–	387.0M
All other segments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3.0M	3.0M	11.0M	22.0M	16.0M	16.0M	20.0M	15.0M	15.0M	10.0M	16.0M	16.0M	15.0M	547.0M	–	–	–	–	–
Corporate and other	5.0M	–	5.0M	4.0M	5.0M	–	5.0M	4.0M	4.0M	–	4.0M	4.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Abbott Laboratories revenue by business segment, last 4 quarters

Business segment	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Medical Devices	$5.9B	$5.5B	$5.4B	$5.4B	46%
Diagnostic Products	$3.1B	$2.2B	$2.3B	$2.2B	25%
Nutritional Products	$2.1B	$2.0B	$2.2B	$2.2B	17%
Established Pharmaceutical Products	$1.5B	$1.4B	$1.5B	$1.4B	12%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Abbott Laboratories revenue by region, last 4 quarters

Region	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Non-US	$7.4B	$6.9B	$7.1B	$6.9B	59%
United States	$5.2B	$4.3B	$4.3B	$4.3B	41%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Abbott Laboratories revenue by country, last 4 quarters

Country	Q2 FY26	Q1 FY26	Q3 FY25	Q2 FY25	Share
Non-US	$7.4B	$6.9B	$7.1B	$6.9B	59%
UNITED STATES	$5.2B	$4.3B	$4.3B	$4.3B	41%

In USD, fiscal quarters as reported; share = part of Q2 FY26 revenue.

Questions and answers

What are Abbott Laboratories's business segments?

Medical Devices, Diagnostic Products, Nutritional Products and Established Pharmaceutical Products (as reported for Q2 fiscal 2026).

Which business segment makes the most money for Abbott Laboratories?

Medical Devices: $5.85 billion, or 46% of revenue, in Q2 fiscal 2026.

Where does Abbott Laboratories make its money?

By region in Q2 fiscal 2026: Non-US (59%) and United States (41%).

MoreAbbott Laboratories stock overview Abbott Laboratories financials Abbott Laboratories executive team Abbott Laboratories shareholders

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Segments by quarter (USD)

Click a bar to see that period below. Striped bars are calculated fourth quarters; an empty slot means it could not be calculated on the same basis i

Medical DevicesDiagnostic ProductsNutritional ProductsEstablished Pharmaceutical ProductsCardiovascular and Neuromodulation ProductsOther OperatingAll other segmentsCorporate and other

Q2 FY26 breakdown

Fiscal quarter ended Jun 30, 2026

Item	Revenue	Share	vs year before
Medical Devices	USD 5.85B	46.5%	+9.0%
Diagnostic Products	USD 3.09B	24.6%	+42.3%
Nutritional Products	USD 2.14B	17.0%	-3.1%
Established Pharmaceutical Products	USD 1.50B	11.9%	+8.4%
Corporate and otheri	USD 5.00M		+0.0%

Sum of items USD 12.59B; corporate items and eliminations USD 5.00M. Shares are of the items shown. Click an item with › to see its parts.

Also reported by:

All periods

Every item and period in one grid. Purple = calculated; "–" = not available.

Item	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23	Q1 FY23	Q4 FY22	Q3 FY22	Q2 FY22	Q1 FY22	Q4 FY21	Q3 FY21	Q2 FY21	Q1 FY21	Q4 FY20	Q3 FY20	Q2 FY20	Q1 FY20	Q4 FY19	Q3 FY19	Q2 FY19	Q1 FY19	Q4 FY18	Q3 FY18	Q2 FY18	Q1 FY18	Q4 FY17	Q3 FY17
Medical Devices	5.9B	5.5B	5.7B	5.4B	5.4B	4.9B	5.1B	4.7B	4.7B	4.5B	4.4B	4.2B	4.3B	3.9B	3.8B	3.6B	3.8B	3.6B	3.7B	3.6B	3.7B	3.3B	3.3B	3.2B	2.4B	2.9B	3.2B	3.1B	3.1B	2.9B	–	–	–	–	–	–
Diagnostic Products	3.1B	2.2B	2.5B	2.3B	2.2B	2.1B	2.5B	2.4B	2.2B	2.2B	2.5B	2.4B	2.3B	2.7B	3.3B	3.6B	4.3B	5.3B	4.5B	3.9B	3.2B	4.0B	4.3B	2.6B	2.0B	1.8B	2.1B	1.9B	1.9B	1.8B	2.0B	1.8B	1.9B	1.8B	–	1.3B
Nutritional Products	2.1B	2.0B	1.9B	2.2B	2.2B	2.1B	2.1B	2.1B	2.1B	2.1B	2.0B	2.1B	2.1B	2.0B	1.8B	1.8B	2.0B	1.9B	2.0B	2.1B	2.1B	2.0B	1.9B	1.9B	1.9B	1.9B	1.9B	1.9B	1.9B	1.8B	1.8B	1.8B	1.9B	1.8B	–	1.8B
Established Pharmaceutical Products	1.5B	1.4B	1.4B	1.5B	1.4B	1.3B	1.3B	1.4B	1.3B	1.2B	1.2B	1.4B	1.3B	1.2B	1.2B	1.3B	1.2B	1.1B	1.2B	1.3B	1.2B	1.1B	1.1B	1.1B	1.0B	1.0B	1.2B	1.2B	1.1B	992.0M	1.1B	1.2B	1.1B	1.0B	–	1.2B
Cardiovascular and Neuromodulation Products	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2.4B	2.3B	2.4B	2.3B	–	2.2B
Other Operating	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	532.0M	486.0M	430.0M	–	387.0M
All other segments	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3.0M	3.0M	11.0M	22.0M	16.0M	16.0M	20.0M	15.0M	15.0M	10.0M	16.0M	16.0M	15.0M	547.0M	–	–	–	–	–
Corporate and other	5.0M	–	5.0M	4.0M	5.0M	–	5.0M	4.0M	4.0M	–	4.0M	4.0M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–